Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

1 in Phase 3

Quick facts

Phase 3 pipeline

triptorelin, goserelin, leuprorelin · Oncology
Triptorelin, goserelin, and leuprorelin are synthetic analogs of gonadotropin-releasing hormone (GnRH) that act as potent agonists, initially stimulating and then downregulating GnRH receptors, leading to a decrease in gonadotropin secretion and subsequently a decrease in sex hormone production.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic

What is Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic's pipeline?

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include triptorelin, goserelin, leuprorelin.

Sector hub: All tracked pharma companies